Silexion Therapeutics Reports New Positive Preclinical Findings Demonstrating Multi-Mechanism Immune Sensitization by SIL204 in KRAS-Driven Cancers Silexion to present SIL-204 data at leading Cancer Symposium designed to feature the latest science in the field of GI cancers New preclinical data demonstrate that SIL204 treatment produced statistically significant upregulation of FAS (CD95), the immune “death receptor,” and statistically significant downregulation of HLA-G, an established immune c

-- First-in-human trial of LBL-051 is enrolling patients with refractory autoimmune diseases to rapidly generate broad proof of concept -- August 4, 2026 - Oblenio Bio (“Oblenio” or “the Company”) today announced that the first patients have been dosed in its Phase 1a first-in-human clinical trial evaluating LBL-051, the company's tri-specific T cell engager targeting BCMA, CD19 and CD3. Specifically engineered for autoimmune patients, LBL-051 is designed to safely induce complete depletion of

Aug. 3, 2026 -- GlycoNex Inc. (TPEx: 4168) today announced that the first patient has been successfully dosed in the First-in-Human (FIH) Phase I clinical trial of GNX1021, the Company's novel glycan-targeting antibody-drug conjugate (ADC), in Japan. The milestone marks GNX1021's transition into clinical development and initiates the generation of the first human data for the Company's lead oncology asset. The start of dosing represents an important value inflection point for GlycoNex. It advan

The FDA Division of Neurology provided positive feedback supporting a regulatory pathway for Privosegtor in acute multiple sclerosis (MS) relapses, addressing a significant unmet medical need The FDA confirmed that existing Privosegtor data can be cross-referenced for a new Investigational New Drug (IND) application in acute MS relapses, planned for submission in the fourth quarter of 2026 Privosegtor, a novel neuroprotective candidate, continues to advance across core neuro-ophthalmology indic

Taisho Pharmaceutical secures exclusive rights to clinically develop, register, and commercialize Kaigene's next-generation FcRn inhibitor, KG006, in Japan. Kaigene will receive a $5 million upfront payment and is eligible for up to a combined total of $22 million and ¥57.5 billion JPY (approximately $351 million) in development, regulatory, and sales milestone payments, plus tiered royalties on net sales. The agreement is expected to establish a robust framework for a three-way multi-regional c

MELBOURNE, Australia and OXFORD, United Kingdom, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Aravax, a clinical-stage biotechnology company developing next-generation, disease-modifying immunotherapies for food allergy, today announces it has received Fast Track designation from the US Food and Drug Administration (FDA) for its lead product, PVX108 for the treatment of peanut allergy. The FDA’s Fast Track program facilitates the expedited development and review of new drugs or biologics that are intended

Broadens CREATE's delivery toolkit with access to Monash's novel LNP chemistries and next-generation targeting technologies. Enables rapid evaluation of diverse binder formats and cell-targeting strategies, accelerating development across multiple immune cell types and therapeutic programs. July 31, 2026 -- CREATE Medicines, Inc. ("CREATE"), a clinical-stage biotechnology company pioneering in vivo immune programming, today announced a strategic research collaboration with Australia's Monash Un

Just days after completing a $10.6bn takeover of lung cancer biotech Nuvalent, GSK is already reaping the rewards with Jideytro (zidesamtinib) having gained US approval in ROS1-positive non-small cell lung cancer (NSCLC). This means the selective ROS1 kinase inhibitor is now indicated for use in American adults with locally advanced or metastatic ROS1-positive NSCLC, provided they have already previously received treatment with a prior ROS1 kinase inhibitor. This is GSK’s first drug for lung ca

Longtime investor OPKO Health increases its position as Cocrystal advances toward norovirus Phase 1b data in late 2026 Aug. 03, 2026 -- Cocrystal Pharma, Inc. (Nasdaq: COCP) ("Cocrystal" or the "Company"), a biotechnology company developing novel antiviral therapeutics, today announced a $5 million investment from OPKO Health, Inc. (Nasdaq: OPK) (“OPKO”), a longtime investor in the Company, has increased its position through a $5 million investment as the Company advances its lead norovirus pro

Aug. 02, 2026 -- Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) today announced that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has approved the investigational new drug (IND) application for an open-label, multicenter Phase Ib/II clinical trial of its proprietary PD-L1/4-1BB bispecific antibody, Opamtistomig (LBL-024), in combination therapy for metastatic colorectal cancer (mCRC). The study is designed to